» Authors » Erich Schacht

Erich Schacht

Explore the profile of Erich Schacht including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 209
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ringe J, Schacht E, Dukas L, Mazor Z
Arzneimittelforschung . 2011 Mar; 61(2):104-11. PMID: 21428245
This is a preplanned subgroup analysis on 318 patients with glucocorticoid-induced osteoporosis (GIOP) from an open, prospective, multi-centered, uncontrolled study on a large cohort of elderly patients with a high...
2.
Schacht E, Ringe J
Arzneimittelforschung . 2011 Mar; 61(1):40-54. PMID: 21355445
Efficacy and safety of a new combination package containing 4 or 12 self-explanatory one-week blisters, each with one tablet of 70 mg alendronate (CAS 260055-05-8) and 7 capsules of 1...
3.
Dukas L, Schacht E, Runge M, Ringe J
Arzneimittelforschung . 2010 Sep; 60(8):519-25. PMID: 20863009
Purpose: In an open observational prospective multicentered study on a cohort of patients with a creatinine clearance of < or = 65 ml/min and diagnosed with the "Esslinger Fall Risk...
4.
Richy F, Dukas L, Schacht E
Calcif Tissue Int . 2008 Feb; 82(2):102-7. PMID: 18239843
The aim of this meta-analysis was to compare the antifall efficacy of native vitamin D to that of its hydroxylated analogs alfacalcidol and calcitriol. Randomized clinical trials comparing oral native...
5.
Dukas L, Schacht E
J Rheumatol Suppl . 2005 Sep; 76:44-6. PMID: 16142851
Low D-hormone syndrome, a disorder related to low creatinine clearance (CrCl), is associated with a roughly 4-fold increase in risk for falls. Known conditions leading to low D-hormone syndrome are...
6.
Ringe J, Faber H, Fahramand P, Schacht E
J Rheumatol Suppl . 2005 Sep; 76:33-40. PMID: 16142849
Treatment with plain vitamin D is a nutritional substitute, while the application of alfacalcidol is an active hormonal therapy. Due to strong feedback regulation, plain vitamin D is not activated...
7.
Scharla S, Schacht E, Lempert U
J Rheumatol Suppl . 2005 Sep; 76:26-32. PMID: 16142848
Inflammatory diseases lead to systemic osteoporosis. Causal factors include increased circulating concentrations of inflammatory cytokines such as interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), glucocorticoid medication, and reduced physical...
8.
Orimo H, Schacht E
J Rheumatol Suppl . 2005 Sep; 76:4-10. PMID: 16142845
Over the last 30 years, several clinical trials have reported the efficacy of D-hormone analogs to treat primary and secondary osteoporosis, and their genomic and nongenomic mode of action have...
9.
10.
Dukas L, Schacht E, Stahelin H
Osteoporos Int . 2005 Jun; 16(12):1683-90. PMID: 15933802
Recently, a low creatinine clearance (CrCl) of < 65 ml/min was described as a new significant and independent risk factor for the number of fallers and falls in a community-dwelling...